Pros | ![]() 5Y returns in the top 25% of the category. ![]() Among most bought funds within the category. ![]() Beats FD returns for both 3Y & 5Y duration. | ![]() Among most bought funds within the category. ![]() Larger AUM within category. ![]() Beats FD returns for both 3Y & 5Y duration. | ||
Cons | - | - |
INDMoney rank | 4/8 | 5/8 | ||
Category,Subcateogry | Equity,Sector - Healthcare | Equity,Sector - Healthcare | ||
Fund Age | 6 Years | 12 Years | ||
Fund Size | 2961 Cr | 8352 Cr | ||
Min Investment | SIP ₹100 Lumpsum ₹100 | SIP ₹100 Lumpsum ₹5000 | ||
Expense Ratio | 0.62% | 0.89% | ||
Exit Load | 0.5% | 1% | ||
Benchmark Index | BSE Healthcare TR INR | BSE Healthcare TR INR |
No of Holdings | 33 | 40 | ||
Top 5 Holdings | Cipla Ltd (8.86%) Cohance Lifesciences Ltd (8.81%) Sun Pharmaceuticals Industries Ltd (8.7%) Ipca Laboratories Ltd (8.16%) Gland Pharma Ltd (4.94%) | Sun Pharmaceuticals Industries Ltd (12.57%) Divi's Laboratories Ltd (9.49%) Lupin Ltd (5.82%) Cipla Ltd (5.62%) Dr Reddy's Laboratories Ltd (5.49%) | ||
No of Sectors | 2 | 1 | ||
Top 3 Sectors | Health (98.46%) Financial Services (1.54%) | Health (100%) | ||
Equity % | 99.58% | 98.58% | ||
Debt % | - | - | ||
P/E | 39.12 | 36.85 | ||
P/B | 5.04 | 5.96 | ||
Credit Quality | - | - | ||
Modified Duration | - | - | ||
YTM | - | - |
1-Month Return | 2.07% | 2.76% | ||
3-Month Return | 3.18% | 7.71% | ||
6-Month Return | -6.44% | 0.03% | ||
1-Year Return | 17.5% | 18.05% | ||
3-Year Return | 27.18% | 26.73% | ||
5-Year Return | 24.55% | 23.19% |
Sharpe | 1.13 | 1.13 | ||
Alpha | 2.49 | 1.66 | ||
Beta | 0.86 | 0.9 | ||
Standard Deviation | 15.15 | 14.97 | ||
Information Ratio | 0.06 | 0.02 |
Description | DSP Healthcare Fund Direct Growth is an equity fund.The fund could potentially beat inflation in the long-run. | Nippon India Pharma Fund - Direct Plan - Growth Plan is an equity fund.The fund could potentially beat inflation in the long-run. | ||
Managers | Chirag Dagli | Sailesh Raj Bhan,Kinjal Desai |